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Abstract 
With recent advances in anti-viral therapy there is an opportunity to eliminate HCV from the 
UK population. HCV is common in incarcerated individuals, with previous estimates 
suggesting ~7% of the UK prison population is anti-HCV antibody positive. Increasing 
diagnosis and treatment of HCV in prison is a priority in seeking to eliminate transmission in 
the general population. Thus the study aimed,  
to assess the impact implementation of: 1. A universal offer of blood borne virus testing 
(UOBBVT) using dry blood spot testing for prisoners at reception to increase diagnosis; 2. 
Telemedicine clinics (TC) within North East England (NEE) prisons to increase HCV treatment 
rates.   UOBBVT was initially implemented at Her Majesty’s Prison (HMP) Durham, 
commencing March 2016. From March 2016 to February 2017, 2,831 of 4,280 (66%) new 
receptions were offered BBV testing. Of these, 1,495 (53% of offered) accepted BBV testing, 
of whom 95 (6.4%) were HCV antibody positive, with 47 of those 95 (49.5%) HCV RNA 
positive, suggesting a prevalence of active infection in the tested population of 3.1% (95% CI 
2.4% to 4.2%). Between August 2015 and October 2017, 80 individuals were seen in the TC 
and 57 (71%) commenced antiviral therapy. Of those with known outcome (n=29), 100% 
achieved sustained virological response. In the year prior to implementation, only 4 patients 
received HCV treatment. In conclusion,a universal offer of BBV testing to inmates presenting 
at HMP reception coupled with linkage into specialist care via TC can substantially increase 
rates of testing, diagnosis and treatment of HCV in this high prevalence population.   
Introduction 
Chronic hepatitis C virus infection (HCV) is a major cause of end-stage liver disease 
worldwide. It is estimated that there are 214,000 HCV infected individuals in the UK, with 
injecting drug use as the major risk factor for HCV acquisition, accounting for approximately 
85% of cases 1. It is known that approximately 60% of individuals who inject drugs have 
been in prison 2, and that 68% of incarcerated individuals have injected drugs the previous 
year 2,3. As a result, HCV is common in incarcerated individuals, with previous estimates 
suggesting ~7% of the UK prison population is HCV antibody (anti-HCV) positive 4. Studies 
from Europe, Australia and the USA suggest that the prevalence of anti-HCV in prison 
populations may be higher still, ranging from 8% to 57% 4,5.  
In the last few years there has been a substantial improvement in the efficacy and 
tolerability of HCV treatments, with the development of direct acting antivirals (DAAs) 6–8. 
Now more than 95% of those treated with an 8 to 12-week oral combination of DAAs 
achieve a sustained virological response (SVR), defined as HCV RNA not detected 3-month 
post treatment, which is accepted as indicating a cure of the infection 9. SVR has also been 
shown to significantly reduce the risk of liver-related complications, hepatocellular 
carcinoma, and both liver-related and all-cause mortality 10,11. These dramatic 
improvements in antiviral therapy present a major public health opportunity, and in 2016 
Public Health England 1 agreed to support the World Health Organisation strategy to 
eliminate HCV as a major public health threat by 2030 12. The WHO goal for incidence 
reduction is 80% for HCV, 95% for HBV and 90% for HBV and HCV combined. 12. 
Given the high prevalence of HCV in prison populations, any programme designed to 
achieve elimination needs to significantly increase the diagnosis and treatment of HCV in 
prisons. In England, however, testing rates in prisons have historically been low (c. 4%), with 
inconsistent approaches across the Health and Justice systems 13. In 2013-4, for example, in 
one of the prisons in North East England (NEE) only 8% of prisoners were tested for HCV, 
with 43% of these being HCV antibody positive 14. At that time, HCV testing was conducted 
by the sexual health team on individuals specifically referred for HCV testing from other 
services (drug and alcohol in-reach, mental health or primary care) within the prison. 
Attendance rates at these testing appointments were low, while the high positivity rate 
suggested a high burden of undiagnosed infection.  
In response to the low rates of HCV testing in UK prisons, in 2013 PHE, NHS England (NHSE) 
and the National Offender Management Service (NOMS) published a Joint Partnership 
Agreement. This partnership recommended that all prisoners should receive a universal 
offer of blood borne virus testing (UOBBVT) at or near to reception into prison. In 2014 the 
NEE “UOBBVT task and finish” group began developing a program to implement UOBBVT in 
all NEE Prisons. In addition, a robust HCV treatment pathway was developed to effectively 
deliver antiviral treatment within the prisons14. This pathway included consultant-led TC 
supported by specialist nurse in-reach. 
Here we present the results of the 1-year pilot of UOBBVT in HMP Durham and the pilot of 
TC HCV treatment clinics in HMP Northumberland. 
Methods 
Development of the BBV testing and treatment pathway 
In 2014 the “task and finish” team was convened to develop a blood borne virus testing 
(BBVT) and treatment pathway for all the prisons in NEE. This team was comprised of public 
health consultants, prison healthcare staff, commissioners, viral hepatitis specialist 
consultants and viral hepatitis specialist nurses.  
The overall initial aims of the group were to optimise BBV testing rates within the NEE HMP 
estate and to expand BBVT opportunities within the whole prison environment.  To achieve 
these aims, an adequately funded UOBBVT program at reception to prison has been 
developed, feeding in to robust treatment pathways. The HCV treatment pathway is 
designed to ensure a high proportion of HCV RNA positive individuals are able to commence 
and complete treatment, either within the prison establishment or in the community if the 
prisoner is released prior to commencing treatment.   
To inform the development of this new service, an audit of HCV testing and treatment rates 
in the NEE Prisons was conducted in 2013/4 to determine baseline activity. To secure 
adequate funding, economic models were developed to assess the fiscal impact of UOBBVT 
and the introduction of consultant Telemedicine HCV clinics 14. 
The project was approved by the Newcastle-upon-Tyne Hospitals NHS Foundation Trust 
clinical governance department (project 8083). 
The Prison Estate in the North East of England (NEE)  
The prison estate in NEE comprises seven facilities. This project was piloted in HMP Durham, 
a large category B male remand prison taking approximately 7,000 receptions awaiting trial 
annually and HMP Northumberland, a large category C male prison with a fairly stable 
population of 1,354 inmates 15. 
The initial pilot of UOBBVT was conducted at HMP Durham before being rolled out in a 
staged manner to other HMPs across the NEE estate. The pilot of consultant-led 
telemedicine HCV clinics was conducted at HMP Northumberland and was also rolled out 
across the prison estate.  
The BBV testing pathway 
Prior to the implementation of the new BBV testing pathway, it was routine practice to use 
standard venepuncture to test for BBV in the prisons. This method, however, was unpopular 
with prisoners, and some of the individuals most at risk of HCV were difficult to obtain blood 
from due to a previous history of injecting drug use. Therefore, in order to maximise uptake 
of BBVT, dry blood spot testing (DBST) was introduced. All prison healthcare staff were 
trained in DBST prior to roll out of the new program and there remains an ongoing program 
of education for current and new staff. HMP Durham has a very high throughput of new 
inmates presenting to reception and thus was considered to be the most appropriate site 
for the UOBBVT testing pilot. Roll out of the UOBBVT to the other NEE prisons was 
implemented after completion of the pilot. 
From March 2016, all prisoners at HMP Durham were to be offered BBV testing at reception 
to the prison using DBST. Inmates presenting within the HMP Durham health system and 
within the general HMP Durham estate were also offered BBVT. Trained staff were available 
at all times to perform the blood testing. Staff were encouraged to be positive when seeking 
consent from prisoners and to indicate that is was routine practice for all inmates to be 
tested for BBVs. 
DBS samples, along with venous blood samples, were sent to the regional Public Health 
Laboratory for testing. 
DBS testing 
DBS samples were tested for HCV, HBV and HIV using Roche Elecsys® Anti-HCV II, Elecsys® 
HIV combi PT and Elecsys® HBsAg II assays on a Cobas® 8100 platform as previously 
described16,17 
DBS samples which were anti-HCV positive results were confirmed using HCV RNA on DBS 
samples 17. HBV and HIV positive results were confirmed as recommended in the national 
standard testing algorithm, on further venous samples. DBS testing and confirmation 
algorithm is shown in figure 1. 
Within 10 days of initial testing, inmates were recalled into HMP healthcare for review of 
their DBST results. Those who had a negative result were informed of this via letter from the 
healthcare team that also advised of viral incubation periods and offered further testing if 
needed. Individuals in receipt of a positive HCV RNA by DBS had a venous sample taken to 
measure HCV viral load and genotype. Any prisoners who were confirmed as being HCV RNA 
positive were referred for treatment. In these consultations, detailed counselling advised 
them about opportunities for treatment and risk reduction.  
For those with a anti-HCV positive , but negative HCV RNA by DBS repeat HCV testing with 
standard venous blood was undertaken to confirm the DBS result in order to rule out false a 
positive antibody result and false negative RNA result.    
BBV testing rates from HMP Durham before and after implementation of 
the new testing pathway 
Baseline BBV testing rates (prior to the initiation of the new BBV testing pathway) at HMP 
Durham (and all other prisons across NEE) were previously assessed for 2013/4 and 
reported by PHE 18. These baseline testing rates were used as a comparator to assess the 
impact of the new UOBBVT. 
Following the implementation of the UOBBVT, data were collected prospectively.  These 
included the number of new receptions who were offered DBST, the number who declined 
testing, the number who tested anti-HCV positive and the number who were HCV RNA 
positive. In addition, data was collected on the total number of BBV tests conducted 
anywhere in the prison. 
New HCV treatment pathway 
Prior to the implementation of TC in HMP Northumberland, HCV positive inmates were 
reviewed in the HCV clinic at the Freeman Hospital, Newcastle, with a maximum of 1 inmate 
per week. Attendance rates were poor, costs for prisoner transport were high and few 
patients ever started treatment.  The new treatment pathway using consultant-led TC with 
viral hepatitis nurse-led prison in-reach clinics was designed to optimize the treatment 
pathway, thus increasing efficiency and treatment rates19. This was fully implemented at 
HMP Northumberland in August 2015. HMP Northumberland houses a more stable prison 
population than other facilities within the NEE prison estate, with many inmates 
undertaking medium lengths of sentence. It was therefore felt to be an ideal prison to test 
the treatment pathway, as the majority of prisoners would be able to complete treatment 
while in custody. 
All individuals found to be HCV RNA positive were offered an assessment for treatment with 
the in-reach viral hepatitis nurse (weekly clinic) similar to a model described previously in 
Australian Prisons 19. At this initial consultation, the nurse obtained an inmate history and 
conducted a physical examination, pre-treatment blood tests, liver ultrasound and transient 
elastography. Once the results of these tests were available, a second consultation was 
conducted via TC video link with the hepatology consultant (TCs being delivered fortnightly 
or monthly depending on demand) and a decision was made whether or not to proceed 
with treatment. All patients were then discussed in the regional hepatitis C multidisciplinary 
meeting and commenced on a combination of DAAs in line with NHS England 
recommendations, if appropriate.  
All HCV RNA positive individuals with a short sentence that precluded commencement of 
antiviral therapy in prison were provided with written information about their diagnosis, 
given details of contacts for community HCV treatment services, and encouraged to access 
treatment upon release from prison.  
Review of treatment rates prior to and after implementation of the 
telemedicine treatment pathway in HMP Northumberland 
A retrospective audit of HCV treatment was conducted in HMP Northumberland in 2013/4 
and formed part of the PHE report in 201418. This provided baseline data on treatment rates 
for comparison with the new treatment pathway. Following introduction of the prison HCV 
TC, data were collected prospectively on HCV RNA positive referral rates, attendance rates 
and antiviral treatment rates. Patients accessing the clinic were also invited to complete a 
short satisfaction questionnaire.  
Results 
A universal offer of BBV testing increases testing rates in HMP Durham 
The UOBBVT pilot commenced at HMP Durham in March 2016. From March 2016 to 
February 2017, 3,309 offers for BBVT were made across the site, with 2,831 of the 4,280 
(66%) new receptions offered BBV testing.  A total of 1,495 (53% of offered, 35% of total) of 
new receptions accepted BBV testing, of whom 95 (6.4%) were anti HCV antibody positive. 
Of these, 47 (49.5%) were HCV RNA positive, confirming a prevalence of active infection in 
3.1% of all tested (95% confidence interval 2.4% to 4.2%). Seven (0.5%) individuals were also 
HBsAg positive and 2 (0.1%) were HIV positive.    
Data from March 2016 to October 2017 (Figure 2) continued to show that 65% of all new 
receptions were offered BBVT, with an uptake of around 50%. The initial and sustained 
uptake of the UOBBVT at HMP Durham illustrates a substantial increase in testing rates 
when compared with 2013-2014 data, in which only 164 of the ˜ 7,000 new receptions 
(2.3%) undertook BBVT. During the UOBBVT pilot phase (March 2016 – Feb 2017), 479 had 
BBV testing after reception. This represents an increase in testing rates more generally in 
the prison when compared to 164 inmates tested across HMP Durham estate in the year 
2013-14 prior to implementation of UOBBVT, suggesting that inmates may decide to accept 
BBVT after the initial contact of the reception stage. 
Common reasons for non-acceptance of the test were inmates stating: “doesn’t want it” 
(54%), “already had test” (37%) or “doesn’t need it” (5.4%) as illustrated in Figure 3.   
What was the outcome for the HCV RNA positive individuals? 
Table 1 shows the outcome of the 47 individuals who were diagnosed with active HCV (HCV 
RNA positive) between March 2016 and February 2017. Overall, 11 (23%) have completed 
antiviral treatment, 3 (6%) have been reviewed in the MDT but not yet commenced 
treatment, 5 (11%) declined to engage in treatment, 1 (2%) died and 1 (2%) is currently 
ineligible for re-treatment, having failed DAA treatment previously. Unfortunately, in 26 
patients (55%) the outcome is unknown as these individuals were released prior to 
commencing antiviral treatment. The relatively low rate of linkage into treatment has 
persisted after the pilot, with only 15% (6 out of 41 HCV RNA positive patients) commencing 
treatment between March 2017 and May 2017, despite there being an active fortnightly 
HCV assessment/treatment clinic in the prison.  
Significant increase in treatment rates with the new TC HCV clinic in HMP 
Northumberland 
Prior to full implementation of the TC HCV clinic in HMP Northumberland, testing and 
treatment rates were low. An audit of activity for the year 2013-2014 (PHE, 2014) illustrated 
that only 102 (8%) inmates were tested for HCV.  Of these, 44 (43%) were anti-HCV positive, 
with 29 (29%) being HCV RNA positive, although only 4 of these individuals (13.8%) started 
treatment in that year.  
TCs were fully implemented in HMP Northumberland from August 2015, with 80 individuals 
being reviewed in this clinic up to October 2017. Of those seen, 57 (71%) commenced anti-
HCV treatment and 42 (73%) are known to have completed treatment in prison, with the 
others being released or transferred to other prisons on treatment. In those with a known 
outcome 100% (n=29; 51%) achieved SVR. Attendance rates at the TC were good at 83%. 
Overall, satisfaction with the TC among the prisoners was very high (80% good or excellent). 
Rollout of UOBBVT to the other NEE prisons 
Roll out of UOBBVT across other prisons in the NEE HMP estate began in March 2017. This 
has resulted in similar increases in BBV offer and testing rates for both new reception and all 
inmates, with notable increases being the uptake of UOBBVT for all inmates in HMP Low 
Newton, rising from 155 for the 12 months from April 2013 to March 2014 to 281 for the 7 
months from April to October 2017, demonstrating an increase from an average of 12 
BBVT/month to 40. HMP Frankland has also seen a significant increase in uptake, from 40 
during the calendar year 2013-2014 to 144 in the 5 months from June to October 2017, 
representing an increase from an average just over 3 BBVT/month to nearly 29 
BBVT/month. 
Since introduction of the BBV testing program, treatment rates have dramatically increased 
across the NEE prison estate. Between February 2017 and January 2018, a total of 159 
commenced antiviral treatment, as shown in Table 2. This is in part due to the increased 
testing rates in Durham as many prisoners who test positive for HCV are transferred to 
other prisons in NEE where they receive treatment. 
 
Discussion 
Hepatitis C is common in prison, with previous estimates suggesting ˜7% of the UK prison 
population carries HCV antibodies, and our own data demonstrating a prevalence of active 
infection of just over 3%. While prison is potentially a good place in which to treat hepatitis 
C by providing a stable environment for prolonged periods of time, testing and treatment 
rates have historically been suboptimal in UK prisons. As a result, in 2013 Public Health 
England, NHS England and the National Offender Management Service published a report 
recommending that all prisoners should receive a universal offer of blood borne virus 
testing (UOBBVT) at reception to prison. Here we have shown that implementation of a 
UOBBVT at reception in one prison significantly increased testing for BBVs from 2.3% to 
35%, leading to many new diagnoses of HCV.  Subsequent rollout of the program to other 
NEE prisons has seen similar increases in testing rates, suggesting that this is a reproducible 
model.  Coupled with the development of the UOBBVT, we have overhauled our prison HCV 
treatment pathway by using telemedicine to improve efficiency of the service. Previously, 
prisoners had to visit the hospital to see a consultant prior to receiving treatment in the 
prison. This was notoriously inefficient with limited numbers of clinic slots and the need for 
expensive prisoner transportation, meaning that relatively few patients ever commenced 
treatment. Since introducing the TC with specialist nurse in-reach in HMP Northumberland 
using a model that has been shown to be effective in Australia 19 , treatment rates have 
increased 10-fold and there has been a notable reduction in clinic non-attendance rates 
from 50% to 17%. 
The prevalence of anti-HCV positivity in HMP Durham was similar to other UK prisons (6.4% 
vs. 7%). However, this is significantly lower than is seen in other countries, such as Australia, 
where the prevalence rate is between 23%-33% 20. The reasons for the significant 
differences is not clear, but could be due to the difference in HCV prevalence in the general 
population, which is known to be higher in Australia than England (0.9% vs 0.3%) In 
addition, there could be differences in the proportion the prison population who are current 
or previous injecting drug users or the rate of HCV in injecting drug users between the 
countries. Moreover, harm reduction methods may differ. It is interesting to note that only 
49.5% of the individuals testing anti-HCV positive were viraemic, which was lower than has 
been seen in other settings. This is thought to be unlikely to be due to patients receiving 
treatment previously as very few had received previous treatment, but might represent a 
high spontaneous clearance rate. Although low specificity of the HCV antibody test (false 
positive antibody) or low sensitivity of the HCV RNA test (false negative RNA) on DBS 
samples are other possibilities, the performance of anti-HCV  and RNA tests on DBS samples 
were extensively validated against paired venous samples from patient with unknown HCV 
status, and simulated DBS samples using known positive & negative samples as per 
regulatory requirements, with high degree of concordance. In addition, venous samples 
were collected from prisoners with a positive anti-HCV but negative RNA result to confirm 
status as described in the testing algorithm above.  
Although there has been a large increase in testing rates among prisoners at first reception, 
overall rates of uptake of BBV testing remain suboptimal at 35%. In order for a BBV testing 
program to be truly “universal opt out”, and consequently highly effective, offer and 
acceptance rates need to be >90%, and further work is needed to optimise testing. The 
major reasons for non-acceptance of the test were “doesn’t want it” (54%) and “already had 
test” (37%).  Reasons why those who didn’t want the test needs further exploration. It may 
be that reception to prison is not the best time to offer individuals BBV testing as this may 
be a stressful time for the new receptions. In addition, reception can be busy (>7000 
receptions/year in HMP Durham), making it difficult to find time to encourage waverers to 
take the test. A significant number of receptions said they had “already had the test”. In this 
pilot we were unable to verify if this was the case, but further work is needed to understand 
the validity of such a claim. Robust mechanisms need to be in place to access previous BBV 
test results, if available, to verify whether inmates have been tested and to reduce duplicate 
testing. Use of a common computer system, with access to electronic health records, across 
the whole UK prison estate will reduce the risk of duplicate testing. 
Previous studies have identified a number of barriers to BBV testing in the incarcerated 
population 21. These include important organisational issues such as lack of a structured 
approach to testing, long waiting times, poor linkage to care for those with a positive test, 
limited knowledge about HCV by prison staff and differing health priorities 21,22. Our work 
has overcome many of these barriers. In addition, there are a number of personal barriers 
to testing such as concerns about stigma and confidentiality, low motivation for testing in 
some individuals 21, lack of understanding around the perceived risk of BBV, lack of 
understanding of the consequences of untreated HCV, and lack of knowledge that it can be 
relatively easily treated with DAAs 23. Our systematic approach to staff training about HCV 
and other BBVs has also helped address some of these barriers, but clearly there is more 
work to do to further increase testing rates. Staff have now routinely embedded BBV testing 
in reception to normalise it. However, there is a regular turnover staff in the prison so an 
ongoing process of education is essential to maintain a high testing rate. Although we have 
not explored the use of incentives for prisoners having a test or staff undertaking the test, 
this might be a way to increase testing rates further and is worthy of a trial. 
Testing rates for BBVs in HMP Durham are now higher than for other prisons in England. 
Data from the 2017 PHE report “Hepatitis C in England” showed that rates of testing for 
BBVs in English prisons has increased from 5.3% on 2010/11 to 11.5% in 2015/6 due to 
some prisons having implemented a UOBBVT, but rates of testing remain well below 
acceptable levels. There are a number of potential reasons for the higher offer and testing 
rates seen in Durham prison compared with other prisons in England. Firstly, the NEE BBV 
testing and treatment pathway group used a systematic approach to introduction of the 
new programme of BBV testing. This incorporated assessment of the cost of 
implementation of the program, achieving specific funding for the program from prison 
healthcare commissioners, developing a thorough training program for staff in the prison 
and introducing robust data collection on outcomes of the program. Secondly, DBST was 
used as the testing method, which is more acceptable than standard venepuncture that is 
still used in many UK prisons. DBST increases the likelihood of individuals accepting a test by 
3-6 fold compared with standard venepuncture 24,25. This technique is also not dependent
on the need for specialist skills in venepuncture, resulting in many more staff being able to 
perform the test 26–28. DBST has very good sensitivity (>96%) and specificity (>98%) for HCV 
29  and has been shown to be a cost- effective screening tool for HCV within the prison 
setting 26, making it a good testing system in prisons 28–30. 
In addition to developing the UOBBVT, we introduced a new treatment pathway to help 
deal with the expected increase in patients diagnosed with HCV and to ensure high rates of 
treatment. This involved the introduction of specialist nurse in-reach clinics with consultant-
led TC, which significantly increased the number of patients treated in HMP 
Northumberland. The pathway was also very efficient in reducing the need for prisoner 
transport, which cost £250-500 per hospital visit. The telemedicine approach was also an 
efficient use of consultant time, allowing the consultant to do the clinic from their hospital 
base where other activities are ongoing. Following the successful introduction of the TC in 
Northumberland Prison, this pathway is now used in other prisons in NEE. In the last year, 
159 patients were commenced on antiviral treatment across the whole Estate, which 
represents a large increase in treatment rates (54 in previous year). Clearly, not all of the 
increase in activity is due to the new treatment pathway. Availability of the new direct 
acting antivirals (DAAs) is also likely to have contributed as more patients are willing to 
undergo treatment with DAAs than with interferon based treatments, which were poorly 
tolerated and had modest HCV clearance rates 6,8,31. 
One of the key success factors of a BBV testing program is to ensure that all BBV positive 
cases are linked into treatment. The pilot work of HCV testing in Durham Prison showed that 
linkage to treatment for those testing positive for HCV was low (~20%). The likely 
explanation for this is that HMP Durham is now entirely a remand prison and, as a result, 
many inmates have a very short prison stay. It is also hard to predict how long inmates will 
be in the prison as they are awaiting court appearances and sentencing. Therefore, a large 
proportion of prisoners have insufficient time in prison to enter the treatment pathway, 
even with weekly nurse in-reach HCV clinics. Although some patients who were diagnosed 
with HCV did not access treatment in the prison, all were given both harm reduction advice 
that may reduce their risk of infecting others and information about HCV and local 
treatment services so they could access treatment on release. Further work is needed to 
assess what proportion are subsequently treated in the community. Importantly, many 
prisoners who have medium or long sentences are transferred to the other NEE prisons 
where telemedicine HCV clinics have been established and so are able to access treatment 
there. Since the introduction of the new testing and treatment pathways, we have seen a 
large increase in the number patients treated in all NEE prisons. Going forward, it is 
important that the diagnostic and treatment pathway for HCV in prison is as simple and 
quick as possible to ensure that a large proportion of inmates commence treatment. There 
have been some recent developments in point of care tests, including a rapid oral anti-HCV 
test 32 and a rapid point of care RNA test 33, which can give a result within an hour. 
Incorporation on these new technologies in the diagnostics pathway could reduce the time 
from positive test to commencing treatment.  In addition, robust arrangements for transfer 
of care and better communication between prisons and community treatment centres when 
patients move prison or are released, should improve treatment rates.  
In conclusion, a universal offer of BBV testing to prisoners at prison reception can 
significantly increase testing rates and lead to many new diagnoses of HCV.  Non-acceptance 
rates remain high, so it is important that there are other opportunities for testing within the 
prison. TC with nurse-led prison in-reach offers a cost effective and efficient method of 
treating HCV in the prison environment.  
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Figure legends 
Figure 1. DBS testing and confirmation protocol. 
Figure 2. Offer and uptake rates for BBV testing in HMP Durham between Mar 2016 and Oct 
2017.  
Figure 3. Reasons for non-acceptance of BBV testing between Mar 2016-Feb 2017. 
Tables. 
Table 1. Outcome of HCV RNA positive individuals at HMP Durham diagnosed between Mar 
2016 and Feb 2017 (n=47). 
Outcome n (%) 
Completed anti-viral treatment 11 (23%) 
Review in the MDT, but treatment not yet 
commenced 
3 (6%) 
Unknown outcome (released from prison) 26 (56%) 
Declined to engage in treatment 5 (11%) 
Deceased 1 (2%) 
Currently ineligible for re-treatment (previous 
DAA failure) 
1 (2%) 
Table 2. Numbers of patients receiving antiviral treatment for HCV in the NEE prisons. 
Prisons Feb 2016-Feb 2017 Feb 2017-Jan 2018 
HMP Frankland 0 9 
HMP Durham 4 18 
HMP Low Newton 0 30 
HMP Northumberland 32 62 
HMP Holme House 18 39 
YOI Deerbolt 0 0 
HMP Kirk Levington 0 0 


